Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) – 2020s to 2020

$3,850.00$5,850.00

Published on: March 24, 2020
Clear
SKU: GMS-2111 Category:

OVERVIEW

The global market for human insulin is expected to hit USD 51.12 billion by 2025, rising from 2020 to 2025 at a CAGR of 6.1%. Demand growth can be due to factors such as increased number of patients with diabetes, increased population exposure to key risk factors contributing to diabetes, increased consumer demand for human insulin analogs, technical developments in human insulin delivery systems and favorable medical reimbursement.

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 1

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 2

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 3

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 4

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 5

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 6

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 7

Human Insulin Market by Applications (Type 2 Diabetes, Type 1 Diabetes), Drugs (Biosimilars, Biologics), Type (Premixed), Brands (Humalog, Lantus, NovoRapid), Delivery Devices (Syringes Pens, Pen Needles) - 2020s to 2020 8

TABLE OF CONTENT

1 Global Human Insulin Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Human Insulin Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Human Insulin Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Human Insulin Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Human Insulin Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Human Insulin Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Human Insulin Market – By Product (Market Size – & million/billion)
8.1 Drugs
8.2 Delivery Devices

9 Global Human Insulin Drugs Market- By Product Type
9.1 Insulin Analogs and Biosimilars
9.2 Human Insulin Biologics

10 Global Human Insulin Drugs Market- By Brand
10.1 Insulin Analogs and Biosimilars
10.2 Human Insulin Biologics

11 Global Human Insulin Delivery Devices Market- By Product Type
11.1 Pens
11.2 Pen Needles
11.3 Syringes

12 Global Human Insulin Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Human Insulin Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Human Insulin Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 ELI Lilly and Company
14.3 Biocon Limited
14.4 Biodel Inc.
14.5 B. Braun Melsungen AG
14.6 Becton, Dickinson and Company
14.7 NOVO Nordisk A/S
14.8 Julphar
14.9 Ypsomed AG
14.10 Sanofi
14.11 Wockhardt Limited
14.12 Company 11 & more

15 Global Human Insulin Market – Appendix
15.1 Sources
15.2 Abbreviations